Octreotide is an investigational synthetic peptide exhibiting actions similar to those of endogenous somatostatin. It has a longer half-life than the native hormone and can be administered by subcutaneous injection. Octreotide inhibits the secretion of growth hormone and numerous regulatory peptides of the gastroenteropancreatic system. Trials evaluating the clinical utility of octreotide indicate efficacy in the management of symptoms associated with acromegaly and hypersecretory neuroendocrine tumors, and in the control of nontumoral secretory diarrheas. Octreotide therapy is well tolerated. This agent should prove useful in the symptomatic control of a number of rare hypersecretory disorders.
Get full access to this article
View all access options for this article.
References
1.
LambertsSWJ. Non-pituitary actions of somatostatin. A review on the therapeutic role of SMS 201–995 (Sandostatin). Acta Endocrinol1986; 112 (suppl 276): 41–55.
2.
BloomSRPolakJM. Somatostatin. Br Med J1987; 295: 288–90.
3.
Data on file, Sandoz Pharmaceuticals Corporation, East Hanover, NJ, 1988.
4.
KrulichLDhariwalAPSMcCannSM. Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro. Endocrinology1968; 83: 783–90.
5.
HellmanBLernmarkA. Inhibition of the in vitro secretion of insulin by an extract of pancreatic alpha-1 cells. Endocrinology1969; 84: 1484–7.
6.
ReichlinS. Somatostatin, parts 1 and 2. N Engl J Med1983; 309: 1495–1501, 1556–63.
7.
MulvihillSPappasTNPassaroEDebasHT. The use of somatostatin and its analogs in the treatment of surgical disorders. Surgery1986; 100: 467–76.
8.
BrazeauP. Somatostatin: A peptide with unexpected physiologic activities. Am J Med1986; 81 (suppl 6B): 8–13.
9.
Somatostatin: Hormonal and therapeutic roles (editorial). Lancet1985; 1: 77–8.
10.
PlessJBauerWBrinerU. Chemistry and pharmacology of SMS 201–995, a long-acting octapeptide analogue of somatostatin. Scand J Gastroenterol1986; 21 (suppl 119): 54–64.
11.
KutzKNueschERosenthalerJ. Pharmacokinetics of SMS 201–995 in healthy subjects. Scand J Gastroenterol1986; 21 (suppl 119): 65–72.
12.
PleweGBeyerJKrauseUNeufeldMDelpozoE. Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201–995 in acromegaly. Lancet1984; 2: 782–4.
13.
LightmanSLFoxPDunneMJ. The effect of SMS 201–995, a long-acting somatostatin analogue, on anterior pituitary function in healthy male volunteers. Scand J Gastroenterol1986; 21 (suppl 119): 84–95.
14.
VanceMLAsplinCMChitwoodJFrohmanLAO'DorisioTThornerMO. SMS 201–995: Studies in acromegaly and in normal men. Scand J Gastroenterol1986; 21 (suppl 119): 243–8.
15.
HashidaSIshikawaETanakaEShimizuNNakagawaKOhtakiS. Serum concentration of human growth hormone after administration of the somatostatin analogue SMS 201–995 in normal subjects. Clin Chim Acta1986; 159: 93–5.
16.
JohnstonDGDaviesRRTurnerSJ. Effects of somatostatin and SMS 201–995 on carbohydrate metabolism in normal man. Scand J Gastroenterol1986; 21 (suppl 119): 158–65.
17.
KohlerEBeglingerCVWhitehouseE. Effects of graded doses of SMS 201–995 on exocrine and endocrine pancreatic function (abstract). Digestion1985; 32.
18.
WilliamsGFuesslHKraenzlinMBloomSR. Postprandial effects of SMS 201–995 on gut hormones and glucose tolerance. Scand J Gastroenterol1986; 21 (suppl 119): 73–83.
19.
WilliamsGBallJABurrinJMJoplinGFBloomSR. Effective and lasting growth-hormone suppression in active acromegaly with oral administration of somatostatin analogue SMS 201–995. Lancet1986; 2: 774–8.
20.
SchluterKJNeufeldMDelpozoEMarbachPCramerHKerpL. Studies in healthy volunteers of a new potent somatostatin analogue: SMS 201–995 (abstract 527). Sixty-fifth annual meeting of the Endocrine Society. San Antonio, TX: Endocrine Society, 1983 (abstract 527).
21.
Del PozoEKutzK. SMS 201–995, a new somatostatin analogue: Pharmacological profile (letter). Neuroendocrinology1985; 7: 111.
22.
KallivretakisNYotisADelpozoEMarbachPMountokalakisTTollisG. Pharmacokinetics of SMS 201–995 in normal subjects and in patients with severe renal failure (letter). Neuroendocrinology1985; 7: 92.
23.
DanielsGHMartinJB. Neuroendocrine regulation and diseases of the anterior pituitary and hypothalamus. In: BraunwardEIsselbacherKJPetersdorfRG, eds. Harrison's principles of internal medicine. 11th ed.New York: McGraw-Hill, 1982: 1694–718.
24.
LambertsSWJDel PozoE. Acute and long-term effects of SMS 201–995 in acromegaly. Scand J Gastroenterol1986; 21 (suppl 119): 141–8.
25.
LambertsSWJZweensMVerschoorLDelpozoE. A comparison among the growth hormone-lowering effects of acromegaly of the somatostatin analog SMS 201–995, bromocriptine, and the combination of both drugs. J Clin Endocrinol Metab1986; 63: 16–9.
26.
BarnardLBGranthamWGLambertonPO'DorisioTJacksonI. Treatment of resistant acromegaly with long-acting somatostatin analogue (SMS 201–995). Ann Intern Med1986; 105: 856–61.
27.
O'DorisioTMO'DorisioMS. Endocrine tumors of the gastroenteropancreatic (GEP) axis. In: MazzaferriEL, ed. Endocrinology. 3rd ed.New York: Medical Examination Publishing, 1986: 764–817.
28.
O'DorisioTM. Gut endocrinology. Am J Med1986; 81 (suppl 6B): 1–7.
29.
Ch'NgJLCAndersonJVWilliamsSJCarrDHBloomSR. Remission of symptoms during long-term treatment of metastatic pancreatic endocrine tumors with long acting somatostatin analogue. Br Med J1986; 292: 981–2.
30.
ShepherdJJSenatorGB. Regression of liver metastases in patient with gastrin-secreting tumour treated with SMS 201–995 (letter). Lancet1986; 2: 574.
31.
ClementsDEliasE. Regression of metastatic VIPoma with somatostatin analogue SMS 201–995 (letter). Lancet1985; 1: 874.
32.
VinikAITsaiSMoattariARCheungPEckhauserFEChoK. Somatostatin analogue (SMS 201–995) in the management of gastroenteropancreatic tumors and diarrhea syndromes. Am J Med1986; 81 (suppl 6B): 23–39.
33.
KvolsLKMoertelCGO'ConnellMJSchuttAJRubinJHahnRG. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med1986; 315: 663–6.
34.
EllisonECO'DorisioTMWolteringEA. Suppression of gastrin and gastric acid secretion in the Zollinger-Ellison syndrome by long acting somatostatin (SMS 201–995). Scand J Gastroenterol1986; 21 (suppl 119): 206–11.
35.
OseiKO'DorisioTM. Malignant insulinoma: Effects of a somatostatin analog (compound 201–995) on serum glucose, growth, and gastro-entero-pancreatic hormones. Ann Intern Med1985; 103: 223–5.
36.
OseiKO'DorisioTMFrankBH. Chronic effects of somatostatin (SMS) analog (201–995) may be independent of suppression of endogenous insulin secretion (abstract). Clin Res1985; 33: 827.
37.
AndersonJVBloomSR. Neuroendocrine tumours of the gut: Long-term therapy with the somatostatin analogue SMS 201–995. Scand J Gastroenterol1986; 21 (suppl 119): 115–28.
SantangeloWCO'DorisioTMKimJGSeverinoGKrejsGJ. Pancreatic cholera syndrome: Effect of a synthetic somatostatin analog on intestinal water and ion transport. Ann Intern Med1985; 103: 363–7.
40.
FedorakRNFieldM. Antidiarrheal therapy: Prospects for new agents. Dig Dis Sci1987; 32: 195–205.
41.
HoeldtkeRDO'DorisioTMBodenG. Treatment of autonomic neuropathy with a somatostatin analogue SMS 201–995. Lancet1986; 2: 602–7.
42.
ChristiansenJYotisA. The role of somatostatin and a long-acting analogue, SMS 201–995, in acute bleeding due to peptic ulceration. Scand J Gastroenterol1986; 21 (suppl 119): 109–14.
43.
LewisETsaiSVinikA. The role of a long-acting somatostatin analogue (SMS 201–995) in the management of a patient with a benign insulin-secreting adenoma of the pancreas and a postoperative pancreatic fistula. Scand J Gastroenterol1986; 21 (suppl 119): 217–22.
44.
ReasbeckPGVan RijAM. The effect of somatostatin on dumping after gastric surgery: A preliminary report. Surgery1986; 99: 462–8.
45.
GerichJE. Rationale for inhibition of growth hormone secretion in the management of the diabetic patient. Scand J Gastroenterol1986; 21 (suppl 119): 154–7.
46.
CamisaC. Treatment of psoriasis with somatostatin analogue 201–995. Paper presented at the Seventeenth World Congress of Dermatology. Berlin, August 1987.
JacksonIBarnardLLambertonP. Role of long-acting somatostatin analogue (SMS 201–995) in the treatment of acromegaly. Am J Med1986; 81 (suppl 6B): 94–9.
49.
LongneckerSM. Somatostatin and octreotide: Literature review and description of therapeutic activity in pancreatic neoplasia. Drug Intell Clin Pharm1988; 22: 99–106.
50.
KatzMDErstadBLRoseC. Treatment of severe cryptosporidium-related diarrhea with octreotide in a patient with AIDS. Drug Intell Clin Pharm1988; 22: 134–6.
51.
LongneckerSM. Remission of symptoms of chemotherapy-refractory metastatic insulinoma using octreotide. Drug Intell Clin Pharm1988; 22: 136–8.
52.
GaginellaTSO'DorisioTM. Octreotide: Entering the new era of peptidomimetic therapy. Drug Intell Clin Pharm1988; 22: 154–5.
